Although highly active antiretroviral therapy has enabled constant progress in reducing HIV-1 replication, in some patients who are « aviremic » during treatment, the problem of insufficient immune restoration remains, and this exposes them to the risk of immune deficiency-associated pathologies. Various mechanisms may combine and account for this impaired immunologic response to treatment. A first possible mechanism is immune activation, which may be due to residual HIV production, microbial translocation, coinfections, immunosenescence or lymphopenia per se. A second mechanism is ongoing HIV replication. Finally, deficient thymus output, gender and genetic polymorphism influencing apoptosis may impair immune reconstitution. In this review we will discuss the tools at our disposal to identify the various mechanisms at work in a given patient and the specific therapeutic strategies we could propose based on this etiologic diagnosis.
Introduction
Highly active antiretroviral therapy (HAART) is increasingly efficient at reducing HIV-1 load. Currently, even with salvage therapy, up to 90% of treated HIV-1-infected adults are « aviremic », i.e. have viral RNA plasma levels under the level of detection of commercially available tests 1 . Consequently, most of these patients reconstitute their immunity under
treatment. Yet, in some patients CD4+ T cell recovery is abnormally low in spite of their full virologic response to HAART. An impaired immunologic response is linked to increased risk of disease progression and death [2] [3] [4] [5] [6] , but we currently have no efficient therapeutic strategy in these situations. It is therefore becoming more and more important to understand the pathophysiological mechanisms responsible for this lack of immune reconstitution, to design assays capable of diagnosing these mechanisms, and to propose therapies adaptated to each situation.
Immunologic responses to HAART : both quality and quantity matter
Peripheral CD4+ T cell increase under treatment is a 3-phase process, whatever the regimen is (figure 1). During the 1 to 6 first months of HAART, the average rate of reconstitution is of 20 to 30 cells/μl monthly [7] [8] [9] [10] . Bosch et al. have estimated this first phase to last for exactly 10 weeks 11 . Most of this initial reconstitution seems to be the consequence of a redistribution of memory CD4+ T cells 12 from the lymphoid tissues towards the blood compartment. The decrease in immune activation induced by the inhibition of viral replication results in a downregulation of adhesion molecules at the surface of CD4+ T cells, including vascular cell adhesion molecule (VCAM)-1 and inter-cellular adhesion molecule (ICAM)-1. As these adhesion molecules are responsible for the trapping of CD4+ T cells into the secondary lymphoid organs, their downregulation provokes the release of these CD4+ T cells into the periphery 13 . The second phase of CD4+ T cell increase, of about 5 to 10 cells/μl monthly
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From lasts until the end of the second year of therapy, and the third phase, of about 2 to 5 cells/μl monthly extends beyond this second year for at least 7 years 10, 12, [14] [15] [16] . Various mechanisms account for the rise in mostly naive CD4+ T cells 12, 17 during these two phases : first, de novo production of T lymphocytes by the thymus ; second, the homeostatic proliferation of the residual CD4+ T cells, and third, the extension of CD4+ T cell half life, a mechanism responsible for sustaining the number of naive CD4+ T cells in older individuals in whom thymic production is impaired 18 . From a qualitative point of view, these three mechanisms of reconstitution are not equivalent. A healthy individual harbours a pannel of T-cells able to recognize a large set of antigens, his T-cell repertoire. HIV-induced CD4+ T cell loss results in the shrinkage of this repertoire. If CD4+ T cell recovery under therapy is based on the production of new CD4+ T cells, this repertoire may be at least partially restored. In contrast, if the increase in CD4 count mainly stems from CD4+ T cell proliferation and survival, the Tcell repertoire will remain truncated, eventhough the total number of CD4+ T cells is normalized (figure 2).
What is an impaired CD4+ T cell restoration on HAART ? Unfortunately there is no consensus on the definition. Some authors have called non immunologic responders patients whose CD4+ T cell count remained below a threshold (e.g., 350 to 500 cells/μl) after a variable period of time of treatment (e.g., 4 to 7 years). For instance, Kelley et al. showed that 24% of individuals with a CD4+ T cell count <500 cells/μl at year 4 of HAART had evidence of a CD4+ T cell count plateau between year 4 and 7,5 19 . It seems preferable to take into account the pre-therapeutic CD4+ T cell count and to define non immunologic responders after their CD4+ T cell slope. A reasonable definition could be a rise in CD4+ T cell count lower than 100 cells/μl after two years of treatment, i.e. less than half of the expected recovery.
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The many determinants of impaired immune reconstitution in virologicresponders
The reason why the drastic reduction in viral load does not always result in the normalization of the CD4+ T cell count may be multifactorial. It is of major importance to understand these various factors at work if we want to establish an etiologic diagnosis and propose an appropriate therapy. Two main mechanisms may result in a suboptimal rise in CD4 count:
insufficient production of CD4+ T cells and excessive CD4+ T cell destruction. Excessive CD4+ T cell destruction may be the consequence of HIV pathogenesis, immune activation
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Thymic output
The level of de novo T cell production is a determining factor for CD4+ T cell recovery.
Many studies have shown that poor CD4+ T cell regeneration is linked to a low proportion of naive cells among CD4+ T lymphocytes [27] [28] [29] [30] [31] . Smith Thus, if ongoing replication occurs in some « aviremic » patients, in lymphoid organs for instance, the cytopathogenicity of the virus may still be at work, particularly if it uses CXCR4
as a coreceptor 31 , and this could hamper the reconstitution of the CD4+ T cell count.
Moreover, Doitsh et al. have recently shown that HIV replicative cycle does not need to be complete to induce CD4+ T cell death 53 .
Immune activation
Many 
Residual viral production
Persistent production of viral particles by reservoir cells in « aviremic » treated patients even in absence of ongoing replication may induce an immune activation. This is due to the anti-HIV immune response and to the fact that various HIV components are able to stimulate the immune system. HIV RNA for instance induces immune cell activation via TLR7 57 , the gp120 envelope through the CD4 receptor and the coreceptors 58 and the accessory protein nef through lipid rafts 59 . All the more so, any ongoing replication should induce immune 9 activation. In line with this, HAART intensification has been reported to decrease immune activation in some patients 60 .
Age
Older persons have a higher background of immune activation than younger ones 61 . This might contribute, in addition to their reduced thymic output, to the link between age and suboptimal CD4+ T cell progression. From a general point of view, immunosenescence might be a cause and a consequence of immune activation, leading to a vicious circle.
High level of CCR5-induced activation
As the main HIV-1 coreceptor, C-C chemokine receptor type 5 (CCR5) is now recognized as a co-activation molecule at the surface of CD4+ T cells 62 , it could be involved in immune activation and thereby in the rise in CD4 count. This could explain why the administration of a CCR5 antagonist resulted in a decrease in T cell activation 63, 64 . Accordingly, a high efficiency of CCR5-induced activation, as a consequence of genetic polymorphism 65 or of a high CD4+ T cell-surface CCR5 density (personal data) may favour the persistence of immune activation under HAART. In support of this notion, Ahuja's group has established a correlation between CD4+ T cell recovery and the genetic polymorphism of the gene encoding CCR5, and the number of copies of the gene encoding one of the natural ligand of this coreceptor, C-C chemokine ligand 3-like 1 (CCL3L1) 65 . In this study, the authors observed that this polymorphism was predictive of the intensity of CD4 count increase in virologic responders. This raises the interesting hypothesis that CCR5, in addition to its virologic roles as an HIV-1 coreceptor, might play a role in immune reconstitution. This hypothesis is in line with the fact that CD4+ T cell restoration is linked to CD4+ T cell surface CCR5 density 66 .
Co-infections
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Another possible source of CD4+ T cell stimulation comes from infectious agents other than HIV. Hepatitis C virus (HCV) co-infection is known to result in a higher level of immune activation 67 . Most but not all authors have linked HCV infection with incomplete CD4+ T cell regeneration [68] [69] [70] . Likewise, cytomegalovirus has been identified as a cause of CD8+ T cell activation in HIV-infected subjects under HAART 71 . Immune activation might also explain why CD4+ T cell restoration after initiation of HAART is impaired in subjects who are co-infected with Mycobacterium Avium complex 72 .
Microbial translocation
It is now established that HIV-1 destroys the CD4+ T cells highly expressing CCR5 that are abundantly present in the gut-associated lymphoid tissues (GALT) early in the infection and that this destruction is partly irreversible, even after years of HAART 73 . One of the consequences of this destruction is that the immune barrier becomes leaky, leaving the way for microbia coming from the gut lumen to invade the organism, a phenomenon called microbial translocation. Microbial translocation has been linked to the proportion of CD8+ T cells overexpressiong CD38, and IFNα concentration in the blood 73 . Therefore, microbial translocation might be one of the driver of immune activation, and thereby of CD4+ T cell loss. In keeping with this notion, high levels of microbial translocation during therapy have been linked to reduced increases in the CD4+ T cell count 74 .
Treg
Interestingly, a low level of regulatory T cell activity, that could account for immune activation, has been linked to failure in CD4+ T cell reconstitution 29 . Yet, the opposite observation has been also reported 54 .
Pre-disposition to immune activation
Genetics may pre-dispose individuals to a high background of immune activation that might be deleterious for immune response under HAART. In keeping with this model, polymorphisms in genes encoding the cytokines IL-6, tumour necrosis factor (TNF)α, and interferon (IFN)α 40 have been involved in HAART-induced CD4+ T cell count gain 75 .
Other genetic factors

Genes involved in apoptosis
Apoptosis is a form of cell death responsible for CD4+ T cell loss during HIV infection. 
Gender
Men have been reported to be at higher risk of non CD4+ T cell response under HAART than women 28, 37 . The reasons for that are unclear. One explanation might be that thymic output is higher in females than in males 35 . Another one could be an anti-apoptotic effect of female sex steroids on CD4+ T cells as observed for instance on neutrophils 77 . Moreover, the level of expression of CCR5 at the surface of CD4+ T cells, linked to CD4+ T cell recovery 66 as above-mentioned, is lower in women than in men 78 .
Other genes
Genetic polymorphisms in the genes coding for the CXCR4-binding chemokine CXCL12 or SDF-1 79 , for the chemokine receptor CX3CR1 79 , and in genes located in the major histocompatibility complex 75, 80 have also been linked to treatment-induced CD4+ T cell restoration.
Other causes
HAART
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Some antiretroviral agents such as AZT may be toxic for haematopoietic progenitor cells 81 , and could thereby hamper CD4+ T cell count reconstitution. Likewise, the combination of tenofovir with high doses of ddI has been involved in poor recovery of CD4+ T cells eventually induced by a deleterious effect of ddI on T cell maturation and differenciation 82 .
On the contrary, a better immunologic response has initially been reported with protease inhibitor 83 . Yet, other studies have shown that CD4+ T cell gain was independent of the antiretroviral regimen 28, 84 . Recently, the integrase inhibitor raltegravir has been shown to induce a greater increase in CD4 count in treatment-naive patients at week 48 but not at week 96 as compared with efavirenz 85 . The same result was reported at week 48 for the CCR5 antagonist maraviroc, that persisted at week 96 86 .
CD4+ T cell nadir
Low nadir CD4+ T cell count 36,54,87 and low pre-therapeutic CD4 count 37,88 have been identified as predictive factors of persistently reduced CD4+ T cell count. Obviously, if the definition of immune response is exclusively based on the CD4 count reached, rather than on the CD4 slope, the baseline CD4 count will definitely influence the level of immune response.
Moreover low nadir CD4+ T cell count and low pre-therapeutic CD4 count may cause emergence of X4 strains 89 , intense microbial translocation 55 , development of co-infections and immunosenescence, all factors hindering CD4+ T cell regeneration as discussed above.
HIV RNA plasma level CD4+ T cell response has been reported to be low when the pre-therapeutic viremia is low 28 .
The reasons for this correlation remain to be unveiled.
How to identify the causes of an impaired CD4+ T cell recovery in a given individual ?
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Now that we have reviewed the potential causes of poor CD4+ T cell progression, failure of thymic activity, ongoing viral replication, and residual immune activation, it is important from a practical point of view to review the tools we have at our disposal to identify the main causes at work in a given patient (table 1) .
Insufficient thymic activity
A weak synthesis of new T cells will result in a low naive T cell / memory Tcell ratio in peripheral blood. But, as other causes may have the same outcome, we need other tools in order to more specifically evaluate thymic activity. Various TREC may be numerated, and the best indicator of thymic activity is the ratio between two of them, the signal-junction (sj)TREC and the βTREC, because this ratio is not modified by cell proliferation 39 . However, determining the sj/βTREC ratio is not a routine assay, and we need more convenient markers.
One of them could be CD31, as the CD31-expressing T cell subpopulation contains the RTE 90 .
Ongoing viral replication
We also need to design routine assays to identify the potential virologic responders in whom For personal use only. on October 31, 2017. by guest www.bloodjournal.org From marker of recent infection, is also not a routine assay 47 .
Other strategies need to be tested, such as, for instance, the detection of HIV DNA in peripheral blood monocytes 52 .
Immune activation
The marker of immune activation that is the best predictor of disease progression might be the percentage of CD8+ T cells that overexpress CD38
92
. But we also need to discriminate between the different causes of immune activation. Residual production of virions may be detected by quantitating the viremia with ultrasensitive techniques 41 . Alternatively, the quantification of unspliced HIV RNA in PBMC might be used to track persistent synthesis of viral particles 93 . Active co-infection may be diagnosed by assays that are specific for the various infectious agents participating in the residual immune activation. High level of CCR5 activation could be detected by genotyping the CCR5 gene and by determining the CCL3L1 gene copy number 65 or by measuring CD4+ T cell surface CCR5 density 66 . Finally, microbial translocation has been initially measured by quantifying lipopolysaccharides (LPS) plasma level 94 , but the quantification of bacterial ribosomal 16S RNA DNA (16S rDNA) plasma level is more sensitive, more specific and more comprehensive 74 .
Therapeutic possibilities
According to the etiology, various therapies may be considered (table 1) .
Insufficient thymic activity
Several options to increase CD4+ T cell restoration might be developed in the next future.
IL-7 is a good candidate because it promotes the maturation of thymocytes, the survival and function of T cells, as well as the homeostatic expansion of all T cell subpopulations 95 . A
phase I/IIa trial has recently shown that administration of IL-7 enhanced T cell recovery in
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From HAART-treated subjects 96 . The limitations might be that lymphopenic patients already produce high amounts of IL-7, and a potential drawback is that by inducing CXCR4 expression, IL-7 might favour the emergence of X4 strains 97 . IL-15 has also been considered to boost immune recovery 98 .
Another option might be to inhibit the production of sex steroids. As estrogens, progesterone and testosterone induce thymic atrophy, probably mainly through their effect on thymic stroma, castration has been tested with success in order to boost thymic activity in animals 99 .
Accordingly, in humans the administration of luteinizing hormone-releasing hormone (LHRH) agonist has resulted in transient enhancement of thymic function 100 , particularly after hematopoietic stem cell transplantation 101 . Obviously, although chemical castration is temporary, the gain in thymic output will have to be balanced with the side effects.
An alternative way to sustain thymic activity is to induce thymic epithelial cell proliferation by using the keratinocyte growth factor (KGF). In mice, KGF administration reverses ageinduced thymic and T cell dysfunction 102 . The effect of KGF after hematopoietic stem cell transplantation is currently being tested.
Finally, growth hormone (GH) is supposed to enhance hematopoiesis and immune function both directly and via insulin-like growth factor 1 103 . GH treatment has been shown to improve thymic function in HIV-1-infected subjects 104 . Yet, here again the risk of adverse events, as carpal tunnel syndrome, hyperglycemia or cancer progression will have to be carefully considered.
Ongoing viral replication
If there is evidence for continuous reinfection of target cells in tissues, the challenge will be to intensify antiretroviral therapy with the aim of stopping this process. Attention should be
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Immune activation
Two strategies may be adopted : on one hand, a symptomatic therapy aiming at reducing the global level of polyclonal immune activation, and on the other hand, etiologic therapies targetting the mechanisms responsible for this activation.
Symptomatic therapy
In the past, various attempts to downregulate the polyclonal immune activation observed in HIV-1-infected patients have been made. These attempts included the use of hydroxyurea, thalidomide, mycophenolate, corticosteroids, IL-10, anti-TNFα agents, cyclosporin A, FK506, and rapamycin 105 . Most of these attempts have been disappointing. If CCR5 is actually involved, as a co-activation molecule, into this immune activation, CCR5 antagonists could exert some inhibitory effect on it. Of note, HAART intensification with the CCR5 antagonist maraviroc has resulted in a decrease in the proportion of activated peripheral blood CD4+ 64 and CD8+ 63 T cells, and in an increase in CD4+ T cell slopes that trended to achieve significance 63 in non-immunologic responders. Thus, agents targeting CCR5 could have an immunological effect sparing CD4+ T cells in addition to their antiviral effects.
Residual viral production
In this case, the way to stop HIV-induced immune activation will be to get rid of the reservoir cells that continue to release virions eventhough these virions do not cause de novo infection.
This goal is presently pursued by some groups with different approaches including the brief induction of viral overexpression with the aim of inducing a cytopathic effect. For this purpose, cytokines as IL-2 or IL-7, activation of protein kinase C, agents remodelling the [100] [101] [102] [103] [104] [105] [106] [107] [108] .
Co-infections
If active co-infections reinforce the global immune activation, the infectious agents responsible for these co-infections might be targeted. Thus, therapeutic clearance of HCV RNA in HIV/HCV co-infected adults has been shown by some authors to decrease immune activation 67 and to improve immune reconstitution under HAART 68 . In the same way, 8
weeks of treatment with valganciclovir of CMV-seropositive HIV-infected patients with CD4+ T cell counts <350 cells/μl after over one year of HAART resulted in a decrease in the proportion of activated CD8+ T cells 109 .
Microbial translocation
The treatment of microbial translocation may be considered in at least two ways. First, if a persisting viral replication in the GALT prevents the reconstitution of the gut-associated immune barrier, intensification of HAART using a regimen of drugs with an efficient gut tissue penetration may be a solution. Second, therapeutic intervention, such as per os administration of probiotics, aiming at modifying the commensal microbiota to reduce the presence of pro-inflammatory bacteria and to increase that of anti-inflammatory bacteria 110 , might be considered.
High level of CCR5 activation
If co-activation signals delivered via CCR5 participate in the maintenance of a high level of immune activation, the administration of CCR5 antagonists might be beneficial.
Finally, the fact that some of the causes of incomplete immune response we have reviewed might be prevented by HAART argues for an early initiation of antiretroviral therapy.
Conclusion
Various mechanisms may be responsible in a given patient for an impaired immune recovery under HAART in spite of a control of viral replication. In order to correctly address this issue we need to design convenient tools to identify which ones of these mechanisms are at work in each non immunologic responder. Based on this personnalized etiologic diagnosis we then will be able to propose specific therapeutic strategies. Beyond the challenge of restoring immunity to prevent AIDS-associated events, the measurement of immune hyperactivation, the identification of the causes of this hyperactivation, and the fight against it will also decrease the risk of non AIDS-linked pathologies.
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